Eoin Comiskey
About Eoin Comiskey
Eoin Comiskey is the Upstream Technical Lead at Bristol Myers Squibb in Dublin, with extensive experience in biopharmaceutical processes and a background in purification and flexographic printing.
Upstream Technical Lead at Bristol Myers Squibb
Eoin Comiskey is currently serving as the Upstream Technical Lead at Bristol Myers Squibb in Dublin. His role involves overseeing upstream processes, ensuring a safe work environment, and maintaining cGMP compliance. Eoin's responsibilities include setting up, executing, and evaluating unit operations such as filtration, chromatography, and UF/DF. He also performs clear documentation following relevant SOPs and acts as a lead investigator SME of the process.
Previous Role at Pfizer
From 2000 to 2018, Eoin Comiskey worked at Pfizer in Dublin as a Purification Process Technician. In this role, he was involved in chromatography and ultrafiltration/diafiltration processing. He worked closely with the maintenance engineering department, ensuring seamless operations within Grade C/D clean room areas. Eoin also managed SAP, LIMS, MCAS, MES, and MCS systems used for batch production, demonstrating a solid understanding of cGMP requirements.
Early Career in Flexographic Printing
Eoin Comiskey began his career in flexographic printing. From 1994 to 1998, he worked as a Flexographic Printer at Boran Packaging in Nass, Kildare. Subsequently, he held a similar role at AB Converters in Blessington, Wicklow, from 1998 to 2000. These positions provided Eoin with valuable experience in the printing industry before his transition to biopharmaceutical science.
Education in Biopharmaceutical and Chemical Sciences
Eoin Comiskey holds a Bachelor's degree in Biopharmaceutical Science from the Institute of Technology, Sligo, earned between 2018 and 2020. He also achieved a Certificate in Science (Chemistry) from the Letterkenny Institute of Technology, where he studied from 1991 to 1993. His educational background provides a strong foundation in both chemistry and biopharmaceutical sciences, complementing his extensive industry experience.